BALTIMORE, MD--(Marketwired - Nov 8, 2013) - In a newly released article, Goldman Small Cap Research, a stock market research firm focused on the small cap and micro cap sectors, notes that yesterday's landmark announcement by Nuvilex Inc. (
This new treatment category represents an even larger opportunity for the company than its current cancer treatment initiatives. According to a report by Transparency Market Research, the global diabetes market for therapeutic devices and drugs is expected to reach US $114.3 billion by 2018.
A proof of principle animal study demonstrated that when cells that produce insulin were transplanted into diabetic animals, the animals' elevated blood sugar levels became normalized and remained stable for the duration of one six-month study. This event indicates that the encapsulated cells produced insulin in response to the higher than normal blood glucose levels in the animals. Therefore, the encapsulated cells appear to have acted as an artificial or replacement pancreas which has tremendous value in treatment of diabetes.
Armed with these valuable study results, management will likely take steps that will ultimately lead to the initiation of human clinical trials which, in turn, will serve to substantially raise the company's value and its profile. Nuvilex is clearly not a one-trick pony and now has multiple shots on goal with the rights to use the cellulose-based live-cell encapsulation technology in developing treatments for both diabetes and cancer.
Moreover, this is now the second time in less than a year that the company has been able to raise funds at a premium to the company's common stock price. The first tranche was $1.5 million at $0.125 per share and the most recent tranche was $1.5 million at $0.15. The stock's most recent closing price was $0.135. Under typical circumstances, the ability to raise funds as a microcap stock for two technology rights acquisitions with virtually no material dilution is a testament to the prospects inherent in the business model. However, to do so at a premium -- twice -- is unheard of and illustrates that management has the capability to raise funds to fund its development objectives.
Coupling the cancer and diabetes markets with its solid R&D results and the proven capability to raise funds indicates that Nuvilex is on the cusp of emerging as a major player on the biotechnology stage. Moreover, an expected 50% or more rise in the share price and overall company valuation as a result of this deal would confirm this sentiment.
This press release contains excerpts of our most recently published article on Nuvilex. To view all of our sponsored Nuvilex reports, updates, articles, disclosures and disclaimers, or to download the article in its entirety, please visit www.goldmanresearch.com.
About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces sponsored and non-sponsored small cap and micro cap stock research reports, articles, daily stock market blogs, and popular investment newsletters. Goldman Small Cap Research is not in any way affiliated with Goldman Sachs & Co.
A Goldman Small Cap Research report, update, newsletter, or article is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read all associated full disclosures, disclaimers, and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit www.goldmanresearch.com.
About Nuvilex, Inc. (